AD

Sec. Sures

#### AWARD NUMBER DAMD17-97-1-7195

. .

TITLE: Determination of the Crystal Structure of Human Zn-Alpha 2-Glycoprotein, A Protein Implicated in Breast Cancer

PRINCIPAL INVESTIGATOR: Dr. Luis Sanchez

CONTRACTING ORGANIZATION: California Institute of Technology Pasadena, California 91125

REPORT DATE: August 1998

TYPE OF REPORT: Annual

PREPARED FOR: Commander U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

DTIC QUALITY INSPECTED 4

REPOR	Form Approved OMB No. 0704-0188				
Public reporting burden for this collection of information is estin gathering and maintaining the data needed, and completing and collection of information, including suggestions for reducing this Dwis Highway, Suite 1204, Arlington, VA 222024302, and to	nated to average 1 hour per response, including the time for revie reviewing the collection of information. Send comments regarding burden, to Washington Headquarters Services, Directorate for b the Office of Management and Budget, Paperwork Reduction Pr	wing instructions, searching existing data sources g this burden estimate or any other aspect of this formation Operations and Reports, 1215 Jefferso oject (0704-0188), Washington, DC 20503.	M		
1. AGENCY USE ONLY <i>(Leave blank)</i>	2. REPORT DATE August 1998	3. REPORT TYPE AND DATES Annual (1 Aug 97 - 3	COVERED 31 Jul 98)		
4. TITLE AND SUBTITLE			5. FUNDING NUMBERS		
Determination of the Crystal St Implicated in Breast Cancer	ructure of Human Zn-Alpha 2-C	Blycoprotein, A Protein	DAMD17-97-1-7195		
6. AUTHOR(S)					
Dr. Luis Sanchez					
7. PERFORMING ORGANIZATION NAME(S) AN California Institute of Technolo Pasadena, California 91125	8. PERFORMING ORGANIZATION REPORT NUMBER				
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research And Materiel Command ATTN: MCMR-RMI-S 504 Scott Street			10. SPONSORING / MONITORING AGENCY REPORT NUMBER		
11. SUPPLEMENTARY NOTES		199906	14 014		
12a. DISTRIBUTION / AVAILABILITY STATEM	ENT		12b. DISTRIBUTION CODE		
Approved for public release; di	stribution unlimited				
<ul> <li>13. ABSTRACT (Maximum 200 words)</li> <li>Zn-α<sub>2</sub>-glycoprotein complex (MHC) accumulates in brue degradation in addinappening in som</li> </ul>	in (ZAG) is a soluble prote proteins. ZAG is present east cysts as well as in 40% ipocytes and appears to be e patients with advanced ca	in related to class I r in most bodily flu of breast carcinoma responsible of the m incer.	najor histocompatibility iids. In addition, ZAG as. ZAG stimulates lipid assive loss of fat tissue		
We have solved the	ne three-dimensional struct	ure of numan ZAG.	•		
ZAG is strikingly A network of hyd ZAG in the absen	similar to class I MHC pro lrogen bonds between ZA ce of B2-microglobulin.	oteins but it does not G's first domains and	bind B2-microglobulin. d the last one stabilizes		
ZAG carries a hy binding groove o ligand in ZAG's f	ydrophobic non-peptidic li f other MHC molecules. V function.	gand in the homolog Ve are studying the i	gous site to the peptide identity and role of this		
14. SUBJECT TERMS			15. NUMBER OF PAGES		
Cachexa Mur	16. PRICE CODE				
17. SECURITY CLASSIFICATION	18. SECURITY CLASSIFICATION OF THIS	19. SECURITY CLASSIFICATION	20. LIMITATION OF ABSTRACT		
OF REPORT Unclassified	PAGE	OF ABSTRACT	Unlimited		
NSN 7540-01-280-5500	1	Standard Form 298	Standard Form 298 (Rev. 2-89)		

- ---- -

-----

NSN	754	0.0	1-28	0.5	500
-----	-----	-----	------	-----	-----

. •

...

.

#### FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

\_\_\_\_\_ Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

\_\_\_\_\_ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

 $\checkmark$  In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

\_\_\_\_\_ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

PI - Signatur

# Table of contents

INTRODUCTION .	2
Subject:	2
Purpose:	3
Previous work:	3
BODY	4
Results:	4
Discussion:	5
Experimental methods:	6
Statement of work:	6
CONCLUSIONS	7
REFERENCES	7

•

# Introduction

### Subject:

Zn- $\alpha_2$ -glycoprotein (ZAG) is a soluble polypeptide of 41 kDa whose name derives from its tendency to be precipitated by zinc ions, its electrophoretical mobility in the  $\alpha_2$  region, and its carbohydrate content. ZAG is present in most bodily fluids, including serum, sweat, saliva, seminal plasma, cerebrospinal fluid, and urine (1). In addition, ZAG is present at high concentrations in about 40% of breast carcinomas, as well as in fluids from breast cysts (2, 3, 4, 5). ZAG is also induced by glucocorticoids and androgens in breast cancer cell lines (6). Taken together, these findings suggest that this protein participates in the development of mammary diseases including breast carcinomas.

Amino acid sequence analysis revealed that ZAG is surprisingly similar to class I major histocompatibility complex (MHC) proteins (7). Class I MHC molecules are cell surface proteins that present cellular peptides to cytotoxic T cells during immune surveillance (8). Each class I MHC protein consists of a membrane-spanning heavy chain associated with a soluble light chain called ß2-microglobulin. Crystal structure analyses reveal that the extracellular portion of the heavy chains fold into a shape ideally suited for peptide binding, including a characteristic groove located between two  $\alpha$ -helices that span an 8stranded B-pleated sheet (9). The amino acid sequence of ZAG shares 30-40% identity with the extracellular portion of the class I MHC heavy chains, therefore ZAG is expected to adopt a similar three dimensional structure. Yet, our results indicate that ZAG is functionally different since it does not bind peptides or ß2-microglobulin (10). The sequencing of ZAG's gene confirmed the structural similarity and functional divergence (11). The coding sequence of the ZAG gene lacks the information for transmembrane or cytoplasmic segments, but otherwise is similar to those of class I genes. By contrast, the non-coding regions of ZAG and MHC genes differ widely in size and sequence. The gene of ZAG lacks the regulatory consensus sequence and interferon consensus sequence that are conserved in typical class I MHC genes. In addition, the gene encoding ZAG also differs of typical class I genes in its lack of polymorphism and in its location outside of MHC. These data indicate that ZAG is a soluble class I MHClike protein that has diverged to develop a different function.

The function of ZAG in physiological and cancerous conditions has remained a mystery until very recently. However, studies from an unexpected direction have begun to clarify it. Approximately half of the patients with advanced cancer suffer cachexia, a massive wasting due to the depletion of the protein and fat stores of the body. Cachexia is a bad prognostic factor and it is believed to be responsible for the death of 20% of cancer patients [Argilés, 1997 #2; Stehle, 1997 #3; Tisdale, 1997 #860]. Tisdale and collaborators have characterized a lipid mobilizing factor from the urine of cachectic patients and identified it as ZAG. Additional experiments have shown that ZAG is overexpressed in cancers of cachectic patients, but not in cancers of non-cachectic patients (12). *In vitro* and *in vivo* assays revealed that ZAG can induce fat catabolism in adipocytes and reduce body mass in mice (13). These data suggest that ZAG is the factor responsible for body fat loss in cachexia. They also suggest that ZAG could regulate fat metabolism in breast tissue and other physiological or pathological conditions.

# Purpose:

-To determine the three-dimensional structure of ZAG.

-To use the knowledge of ZAG's structure for understanding the function of ZAG and its relationship with classical MHC molecules.

### Previous work:

The results of my previous work are in (10). Briefly...

Purification of ZAG: Structural studies require milligram amounts of pure protein. Therefore, I used fluid from breast cysts as a rich source of ZAG and developed a protocol for the isolation of ZAG. I purified the sample by hydrophobic chromatography, then by immobilized nickel affinity chromatography and finally by size exclusion chromatography. This procedure yielded 30 mg of ZAG per 100 ml of fluid.

Analysis of the interaction between ZAG and ß2-microglobulin: The heavy chains of all characterized MHC class I proteins bind ß2-microglobulin with high affinity. However, purified preparations of ZAG show a single band of 41 kDa on an SDS PAGE gel, with no sign of a 12 kDa ß2-microglobulin light chain. In order to ascertain if ZAG binds ß2-microglobulin, I incubated mixtures of both proteins in different conditions, and tried to detect the possible ZAG-ß2-microglobulin complexes by several methods. These included gel filtration chromatography, ELISA, cross-linking and immunoprecipitation, but no complexes of ß2-microglobulin with ZAG were detected. Next, I used anti-ZAG and anti-ß2-microglobulin antibodies to immunoprecipate proteins from serum. The results indicated that serum contains free ZAG and free ß2-microglobulin, but no appreciable amounts of ZAG associated with ß2-microglobulin. Thus, ZAG does not bind ß2-microglobulin.

Analysis of the possible peptides bound to ZAG: I tested acid eluates from purified ZAG and a purified class I MHC molecule  $(H-2K^d)$  for the presence of bound peptides. N-terminal sequencing revealed the presence of peptides in the K<sup>d</sup> acid eluate, but no peptides in the ZAG eluate, demonstrating that ZAG does not bind peptides.

Thermal stability of ZAG: MHC class I heavy chains are unstable in the absence of peptide or the  $\beta$ 2-microglobulin light chain (14), whereas ZAG exists as a class I heavy chain-like monomer without bound peptides. In order to compare the thermal stability of ZAG with a class I molecule, I obtained a melting curve for ZAG by recording the circular dichroism signal at 223 nm as a function of increasing temperature. Melting curves are characterized by their temperature at the transition midpoint or T<sub>m</sub>, with a higher T<sub>m</sub> indicating a more stable protein. ZAG denatures with a T<sub>m</sub> of 65°C, as compared to 57°C for peptide-filled H-2K<sup>d</sup> and 45°C for empty K<sup>d</sup> (15). Thus, unlike conventional class I MHC molecules, ZAG does not require a light chain or bound peptide to fold into a stable structure.

Production of monoclonal antibodies against ZAG: The availability of pure ZAG allowed the production of monoclonal antibodies. I characterized nine monoclonal antibodies that react to ZAG, which were used in co-crystallization attempts with ZAG and for immunoaffinity purification of ZAG.

Crystallization of ZAG: I made numerous crystallization experiments with the pure protein, but I did not obtain crystals, even after repeated trials. Therefore, I subjected ZAG to different treatments, in order to control the potential variables that could be inhibiting its crystallization. These experiments included partial and total deglycosylation of ZAG, controlled proteolytic digestions, removal of potential ligands and co-crystallization of ZAG with fragments of different monoclonal antibodies. Eventually, I was able to obtain crystals of desialiated ZAG, but the crystals were not adequate for x-ray diffraction experiments. Additional analysis using non-denaturing gels demonstrated that ZAG purified from breast cyst fluid was less homogeneous than plasma ZAG. I therefore purified ZAG from commercially available human plasma using immunoaffinity chromatography followed by anion exchange and hydrophobic chromatography. This strategy yielded 8 mg of ZAG per liter of plasma, which allows an ample protein supply for crystallization trials. Using a sparse matrix factorial screening method (16), I obtained well ordered crystals in 30% PEG 4000, 0.1 M sodium acetate pH 4.6, 0.2 M ammonium acetate.

Data collection from ZAG crystals: ZAG crystallizes in space group  $p_{2_12_12}$  with unit cell dimensions of 105 Å x 132 Å x 118 Å. The crystals diffracted to ~ 5 Å resolution at room temperature using an RAXIS image plate detector mounted on a rotating anode generator. The radiation sensitivity of ZAG crystals made it impossible to collect high resolution data at room temperature. However, by transferring protein crystals to a proper cryoprotectant, the crystals can be flash-cooled under a stream of nitrogen gas at -165°C. At this temperature, radiation decay is virtually eliminated (17) and I could use the high intensity of synchrotron radiation to collect high resolution reflections. Using this method, the effective resolution limit of the ZAG crystals extended to ~3.2 Å at Cornell High Energy Synchrotron Source (CHESS).

# Body

#### Results:

The determination of the three-dimensional structure of a protein by x-ray crystallography is a process accomplished in several steps. The first step is the isolation of milligram amounts of protein that is pure, both chemically and conformationally. The second step is the production of crystals of the purified protein that diffract to atomic or near atomic resolution. The third step is the analysis of crystals under x-rays. These steps were already accomplished at the beginning of this project. However, data obtained by x-ray analysis are not enough to solve the structure of macromolecules. Each datum has to be complemented by an additional value, its "phase", in order to reconstruct the three-dimensional image of the molecule. To obtain those phases, I followed two parallel strategies, molecular replacement (MR) and multiple isomorphous replacement (MIR).

MR is a purely computational approach that provides phase information by replacing the unknown structure by the structure of a related protein that is already known. The corresponding phases are biased towards the related protein, but they can be adequate as initial values to be refined. I tried molecular replacement with many models, including class I MHC, class II MHC, and class I homologs like FcRn, CD1, and HFE. I also tried diverse fragments and combinations of those models. However, these attempts remained unsuccessful for many months. Therefore, I concentrated my efforts in the alternate strategy, MIR.

MIR is an experimental approach where protein crystals are soaked with different compounds containing heavy atoms. The x-ray data sets of the soaked crystals are compared with the data set from a control crystal by Patterson analysis. In favorable conditions, the comparison will allow to calculate the phases. The search for the right soak can require many trials and the available time at synchrotron sources is limited. Therefore, I varied my crystallization conditions until I got crystals that diffract to higher resolution (2.9 Å) without requiring synchrotron sources of x-rays. Then, I analyzed hundreds of crystals soaked with different heavy atom compounds and collected approximately forty data sets in the search for the right compound. Eventually, the analysis of six data sets from crystals soaked with mercury acetate and platinum tetrachloride provided initial phase values.

The initial phase values were refined taking advantage of the constrains imposed by solvent flipping and non crystallographic symmetry. The resulting electron density map allowed the trace of the chain of ZAG in the four molecules that are present in the asymmetric unit. The model is still being subject to alternate cycles of model building with O, and refinement with X-PLOR. At present, the model includes all diffraction data between 20 and 2.9 Å and has an Rfree of 30.9% (Rcryst 26.1%). It includes all the residues of ZAG, except the first five residues and the last three ones, which appear to be disordered. The model also includes ZAG's carbohydrate chains, except the most distal residues.

# Discussion:

ZAG has a "L" shape that is very similar to the ones of the class I MHC heavy chains. Considering that the MHC heavy chains are stabilized by the packing of  $\beta$ 2-microglobulin against the angle of the "L", it is surprising that ZAG can attain its remarkable stability without interacting with  $\beta$ 2-microglobulin. Analysis of the structure shows that ZAG has a stabilizing hydrogen bond network between its first two domains and the third one, which are forming the two sides of the "L". The surface area buried in the interface between those domains is also bigger in ZAG (880 Å<sup>2</sup>) than in MHC molecules (500 Å<sup>2</sup>).

The most striking result of the crystallization analysis is the presence of additional nonpeptidic electron density in the place homologous to the peptide binding groove of class I MHC molecules. This additional electron density is surrounded by aromatic residues from ZAG. These observations indicate that ZAG indeed carries a hydrophobic nonpeptidic ligand. Therefore, the role of ZAG in lipid mobilization could be due to ZAG itself, or could be due to the ligand carried by ZAG. I am currently using gas chromatography and mass spectrometry to identify ZAG's ligand. Experimental methods:

Data collection: Cryoprotected crystals of ZAG were flash-cooled by dipping them in liquid nitrogen. The cooled crystals were mounted under a stream of nitrogen gas at -165°C. The x-ray diffraction pattern of the crystals was collected by using a Rigaku rotating anode x-ray generator and a RAXIS2 image plate detector. Data were processed and scaled with the HKL software package (18).

Phase determination: I tried to obtain the phases for each x-ray reflection by molecular replacement using AMoRE (19). This strategy was unsuccessful, therefore, I obtained the phases by molecular isomorphous replacement using the program Sharp (20) helped by programs of the software package CCP4 (21).

Phase refinement: The initial phase values were refined by solvent flipping using Solomon, from the CCP4 package. There are four molecules of ZAG in the asymmetric unit. So, after calculating the non crystallographic symmetry axes, the phases were further refined using DM, from the CCP4 package.

Model building and refinement: ZAG's sequence has been built in the electronic density of each molecule in the asymmetric unit using the program O (22). The model is being refined with X-PLOR (23).

#### Statement of work:

Objective 1: Determination of the three dimensional structure of ZAG Task 1: Months 1-8: Molecular replacement analysis of data from crystals of native ZAG. Completed. Task 2: Months 1-8: Search for heavy atom derivatives of ZAG crystals. Completed. Task 3: Months 9-15: Data collection of heavy atom derivatives of ZAG crystals. Completed. Task 4: Months 16-24: Determination of ZAG crystal structure by combination of the results from task2 and tasks 2-3. Task planned for next year. Objective 2: Comparison of the structure of ZAG with the structures of MHC proteins Task 5: Months 25-30: Task planned for the final year. Objective 3: Analysis of the function of ZAG Task 6: Months 9-21: Extraction, isolation and identification of the ligand or ligands of ZAG.

Task planned for next year.

Task 7-9:

Tasks planned for the final year.

# Conclusions

The three-dimensional structure of ZAG is solved. The parameters are already acceptable, but I think that they can be improved further because the refinement is still in progress and because the crystals will diffract better at a synchrotron.

The three-dimensional structure reveals that ZAG carries a non-peptidic hydrophobic ligand.

# References

1. T. Tada, et al., Journal of Histochemistry & Cytochemistry 39, 1221-1226 (1991).

2. N. J. Bundred, W. R. Miller, R. A. Walker, *Histopathology* 11, 603-610 (1987).

3. L. M. Sánchez, F. Vizoso, I. Díez-Itza, C. López-Otín, *Cancer Research* 52, 95-100 (1992).

4. I. Díez-Itza, et al., European Journal of Cancer 29A, 1256-1260 (1993).

5. J. P. Freije, A. Fueyo, J. Uría, C. López-Otín, Febs Letters 290, 247-249 (1991).

6. Y. S. López-Boado, I. Díez-Itza, J. Tolivia, C. López-Otín, Breast Cancer Research and Treatment 29, 247-258 (1994).

7. T. Araki, et al., Proceedings of the National Academy of Sciences of the United States of America 85, 679-683 (1988).

8. A. Townsend, H. Bodmer, Ann. Rev. Immunol. 7, 601-624 (1989).

9. P. J. Bjorkman, P. Parham, Ann. Rev. Biochem. 90, 253-88 (1990).

10. L. M. Sánchez, C. López-Otín, P. J. Bjorkman, Proc. Natl. Acad. Sci. USA 94, 4626-4630 (1997).

11. J. P. Freije, et al., Genomics 18, 575-587 (1993).

12. P. T. Todorov, et al., Cancer Research 58, 2353-2358 (1998).

13. K. Hirai, H. J. Hussey, M. D. Barber, S. A. Price, M. J. Tisdale, *Cancer Research* 58, 2359-2365 (1998).

14. A. Townsend, et al., *Nature* **340**, 443-448 (1989).

15. M. L. Fahnestock, I. Tamir, L. Narhi, P. J. Bjorkman, Science 258, 1658-1662 (1992).

16. J. Jancarik, S. H. Kim, J. Appl. Crystallography 24, 409-411 (1991).

17. H. Hope, Annu. Rev. Biophys. Biophys. Chem. 19, 107-126 (1990).

18. Z. Otwinowski, W. Minor, *Methods in Enzymology* 276, 307-326 (1997).

19. J. Navaza, Acta Cryst. A50, 157-163 (1994).

20. E. de La Fortelle, G. Bricogne, Methods Enzymol. 276, 472-494 (1997).

21. C. C. P. 4, Acta Cryst. D50 (1994).

22. T. A. Jones, J. Appl. Cryst. 11, 268-272 (1978).

23. A. T. Brünger, X-PLOR, v3.1 A System for X-ray Crystallography and NMR (Yale University, New Haven, CT, 1992).